Exploring the Potential Role of EGFR Inhibitors for Metastatic Melanoma Patients With NF1 Mutations
Increased activity in a specific biological pathway may explain why many patients with advanced melanoma do not respond to immune checkpoint inhibitors, a new study in Cancer Research shows.